Orserdu (elacestrant) is the first treatment for people with ESR1 mutations, which can drive resistance to standard hormone therapy.

Women who received a combination of Kisqali and hormone therapy lived twice as long without their cancer getting worse.

Adding an AKT inhibitor to fulvestrant doubled progression-free survival for patients with HR-positive, HER2-negative breast cancer.

Assay can also help identify patients who may benefit from ovarian suppression therapy.

Blogger Daniel Zeller reports that many conditions have returned to where they were before radiation therapy for his prostate cancer

Patients whose treatment was guided by measurement of tumor cells in the blood had improved survival outcomes.

Most women who interrupted endocrine therapy were able to conceive, and more than 60% gave birth.

Genomic testing is an important tool to guide treatment decisions among women with early-stage breast cancer.

After radiation and hormone therapy for prostate cancer, Daniel Zeller talks with his doctor about PSA numbers and side effects.

Black women were more likely to benefit than white women if treated at an earlier disease stage but less likely at a later stage.